A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer.

Gitlitz, Barbara J

A randomized, placebo-controlled, multicenter, biomarker-selected, phase 2 study of apricoxib in combination with erlotinib in patients with advanced non-small-cell lung cancer. [electronic resource] - Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer Apr 2014 - 577-82 p. digital

Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

1556-1380

10.1097/JTO.0000000000000082 doi


Adenocarcinoma--drug therapy
Adenocarcinoma, Bronchiolo-Alveolar--drug therapy
Adult
Aged
Aged, 80 and over
Antineoplastic Combined Chemotherapy Protocols
Biomarkers, Tumor--urine
Carcinoma, Non-Small-Cell Lung--drug therapy
Carcinoma, Squamous Cell--drug therapy
Cyclooxygenase 2 Inhibitors--therapeutic use
Disease Progression
Double-Blind Method
Erlotinib Hydrochloride
Female
Follow-Up Studies
Humans
Lung Neoplasms--drug therapy
Male
Middle Aged
Neoplasm Recurrence, Local--drug therapy
Neoplasm Staging
Prognosis
Prospective Studies
Prostaglandins--urine
Protein Kinase Inhibitors--therapeutic use
Pyrroles--therapeutic use
Quinazolines--therapeutic use
Sulfonamides--therapeutic use
Survival Rate